July 2017, Vol 7, No 7

A change in leadership brings with it healthcare reform and potential changes in drug pricing in the United States, said Jessica Turgon, MBA, Principal, ECG Management Consultants, Washington, DC, at the 2017 Association of Community Cancer Centers meeting. Ms Turgon discussed what this transition of power means for cancer centers, and what oncology providers can realistically expect under the Trump administration. Read More ›

Advances in immunotherapy are benefiting increasing numbers of patients living with cancer. Since 2011, the FDA approved 15 immunotherapies in oncology, including 5 immunotherapy drugs in 2016. Read More ›

Read More ›

Read More ›

Read More ›

With the release of the final rule of the Medicare Access and CHIP Reauthorization Act (MACRA), participating providers will now be reimbursed by the Centers for Medicare & Medicaid Services (CMS) based on the quality of the care they provide rather than on the volume. Read More ›

Read More ›

The Oncology Care Model (OCM) is a physician-led specialty care model that is aimed at providing higher quality, more highly coordinated oncology care at the same or lower cost to Medicare beneficiaries. Read More ›

he cost of cancer care is rising quickly, and, as a result, oncology is moving away from the fee-for-service payment model toward the Oncology Care Model (OCM). Read More ›

Read More ›